CHARACTERIZATION OF 2 DIFFERENTLY GLYCOSYLATED MOLECULAR-SPECIES OF YEAST-DERIVED HEPATITIS-B VACCINE CARRYING THE PRE-S2 REGION

被引:1
|
作者
KOBAYASHI, M [1 ]
ASANO, T [1 ]
OHFUNE, K [1 ]
KATO, K [1 ]
机构
[1] TAKEDA CHEM IND LTD,HIKARI PLANT,YODOGAWA KU,OSAKA 532,JAPAN
关键词
HEPATITIS-B VACCINE; S + PRE-S2; SUGAR CHAINS; IMMUNOGENICITY;
D O I
10.1016/0168-1656(92)90003-R
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Modified hepatitis B virus surface antigen M protein particles (HBsAg M-P31c) produced in yeast is mainly composed of two differently glycosylated proteins, GP37 and GP34. GP37 has an N-linked sugar chain and O-linked sugar chains; and GP34 has an N-linked sugar chain bound to the peptide backbone P31. Although M-P31c vaccine elicits both anti-S and anti-pre-S2 antibodies, whether there are any differences between GP37 and GP34 in the ability to elicit these antibodies is still unknown. To clarify this issue, we prepared particles which were composed solely of GP37 or GP34 by affinity chromatography, using polymerized human serum albumin as a ligand and digestion with alpha-mannosidase. We also prepared particles composed solely of P31 by successive digestion with alpha-mannosidase and endo-beta-N-acetylglycosaminidase H. The vaccines derived from these three kinds of particles elicited both anti-S and anti-pre-S2 antibodies in mice to the same extent as the original M-P31c vaccine. These results suggest that the N- and O-linked sugar chains of M-P31c component proteins produced in the host yeast cells have no effect on the ability to elicit anti-S and anti-pre-S2 antibodies and that there are no differences with respect to antibody response in mice between the two major components of M-P31c, GP37 and GP34.
引用
收藏
页码:155 / 162
页数:8
相关论文
共 50 条
  • [41] Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine
    Daniel Shouval
    Hedwig Roggendorf
    Michael Roggendorf
    Medical Microbiology and Immunology, 2015, 204 : 57 - 68
  • [42] Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine
    Shouval, Daniel
    Roggendorf, Hedwig
    Roggendorf, Michael
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2015, 204 (01) : 57 - 68
  • [43] DISSOCIATED ANTIBODY-RESPONSES TO THE S AND PRE-S2 REGIONS OF THE HEPATITIS-B VIRUS AFTER VACCINATION IN HEMOPHILIACS
    ZANETTI, A
    TANZI, E
    MANNUCCI, PM
    JOURNAL OF MEDICAL VIROLOGY, 1989, 28 (03) : 156 - 158
  • [44] HLA LINKED IMMUNE-RESPONSE TO S AND PRE-S2 GENE-PRODUCTS IN HEPATITIS-B VACCINATION
    MARESCOT, MR
    BUDKOWSKA, A
    PILLOT, J
    DEBRE, P
    TISSUE ANTIGENS, 1989, 33 (05): : 495 - 500
  • [45] CLONING, EXPRESSION AND CHARACTERIZATION OF A MURINE HUMAN CHIMERIC ANTIBODY WITH SPECIFICITY FOR PRE-S2 SURFACE-ANTIGEN OF HEPATITIS-B VIRUS
    JIN, BR
    RYU, CJ
    PARK, SS
    NAMGUNG, U
    HONG, HJ
    HAN, MH
    MOLECULAR IMMUNOLOGY, 1993, 30 (18) : 1647 - 1654
  • [46] PROTECTIVITY OF A RECOMBINANT PRE-S2 HEPATITIS-B VACCINE IN CHIMPANZEES AFTER CHALLENGE WITH HBV-105 (SUBTYPE-ALPHA-D)
    EDER, G
    SCHAFF, Z
    DORNER, F
    HEPATOLOGY, 1989, 10 (04) : 691 - 691
  • [47] EXPRESSION OF PRE-S1, PRE-S2, AND C-PROTEINS IN DUCK HEPATITIS-B VIRUS-INFECTION
    YOKOSUKA, O
    OMATA, M
    ITO, Y
    VIROLOGY, 1988, 167 (01) : 82 - 86
  • [48] HEPATITIS-B VIRUS NUCLEOCAPSID PRE-S2 FUSION PROTEINS EXPRESSED IN ATTENUATED SALMONELLA FOR ORAL VACCINATION
    SCHODEL, F
    MILICH, DR
    WILL, H
    JOURNAL OF IMMUNOLOGY, 1990, 145 (12): : 4317 - 4321
  • [50] Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine
    Shapira, MY
    Zeira, E
    Adler, R
    Shouval, D
    JOURNAL OF HEPATOLOGY, 2001, 34 (01) : 123 - 127